PROM1 and cancer: Studies from both normal and cancer stem cell lines have indicated that CD133 antibody reactivity is reduced when cells are in the G1/G0 portion of the cell cycle as opposed to the G2/M phase of the cell cycle, suggesting some level of cell cycle dependence related to CD133 expression [41].